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Summary Temozolomide (CCRG 81045: M&B 39831: NSC 362856) is an analogue of mitozolomide display-
ing similar broad spectrum activity in mouse tumours, but showing considerably less myelosuppression in the
toxicology screen. Temozolomide was initially studied intravenously at doses between 50-200 mgm2 and
subsequently was given orally up to 1,200 mg m-2. A total of 51 patients were entered on the single dose
schedule. Temozolomide exhibits linear pharmacokinetics with increasing dose. Myelotoxicity was dose
limiting. Experimentally, temozolomide activity was schedule dependent and therefore oral administration was
studied as a daily x 5 schedule between total doses of 750 and 1,200 mg m'2 in 42 patients. Myelosuppression
was again dose limiting. The recommended dose for Phase II trials is 150mgm-2 po for 5 days (total dose
750 mg m-2) for the first course, and if no major myelosuppression is detected on day 22 of the 4 week cycle,
the subsequent courses can be given at 200 mg m-2 for 5 days (total dose 1 g m-2) on a 4 week cycle. Mild to
moderate nausea and vomiting was dose related but readily controlled with antiemetics. Clinical activity was
detected using the 5 day schedule in four (2CR, 2PR; 17%) out of 23 patients with melanoma and in one
patient with mycosis fungoides (CR lasting 7 months). Two patients with recurrent high grade gliomas have
also had partial responses. Temozolomide is easy to use clinically and generally well tolerated. In the extended
Phase I trial temozolomide only occasionally exhibited the unpredictable myelosuppression seen with mitozo-
lomide.
Stevens and colleagues (1984) synthesised a series of imid-
azotetrazine derivatives which exhibited broad-spectrum anti-
tumour activity against murine tumours. The lead compound
in this series, mitozolomide, has been extensively studied and
is considered to exert its effect by crosslinking DNA (Gibson
et al., 1984 and 1985).
Mitozolomide is a pro-drug of the cytotoxic triazene
MCTIC (Stevens et al., 1984). The major site of alkylation
by MCTIC is thought to be the O6-position of guanine
(Gibson et al., 1985) with additional alkylation also occurr-
ing at the N7 position (Hartley et al., 1986).
Structurally temozolomide lacks the chloroethyl side chain
present in mitozolomide and has been developed as a poten-
tial alternative to dacarbazine (Stevens et al., 1987). Bull and
Tisdale (1987) showed that there were differences in the
ability of mitozolomide and temozolomide to alkylate DNA.
At physiological pH temozolomide undergoes chemical deg-
radation to MTIC without the requirement of metabolic
activation as in the case of dacarbazine (Figure 1) (Stevens et
al., 1987; Tsang et al., 1991).
The Phase I trial of mitozolomide was completed in 1985
(Newlands et al., 1985) and a number of phase II studies
were performed which showed minor antitumour activity in
small cell carcinoma of the lung and in malignant melanoma,
but severe and unpredictable myelosuppression precluded its
further clinical development (Heriat et al., 1988; Blackledge
et al., 1989; Harding et al., 1988; Neijt et al., 1987; van
Oosterom et al., 1989; Gundersen et al., 1987; Schornagel et
al., 1986). Temozolomide was selected for further clinical
development in view of its good experimental antitumour
activity (Stevens et al., 1987) and much lower toxicity in the
pre-clinical screen. In the pre-clinical toxicology a toxic dose
for temozolomide could not be obtained because of the
toxicity of the solvent DMSO but was >420mgm-2. In
addition, unlike mitozolomide, the antitumour activity of
temozolomide was schedule-dependent (Stevens et al., 1987).
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Materials and methods
Temozolomide for clinical use was supplied by the Depart-
ment of Pharmaceutical Sciences, Aston University, Bir-
mingham and was synthesised by May and Baker Limited,
Dagenham, Essex. The i.v. preparation was formulated as a
3% (w/v) solution in DMSO. Ampoules were stored at
-20°C. Temozolomide was administered as a 1 h infusion
after prior dilution in 500 ml of normal saline. Handling
precautions for the i.v. preparation included wearing two
pairs of latex gloves, preparing the drug in a safety cabinet
and using polypropylene syringes and polyfusor plastic to
avoid the solvent action of DMSO. Temozolomide was given
orally in the form of hard gelatin capsules containing 20, 50,
100 or 250 mg to fasted individuals.
All patients entered in this study had advanced cancer
refractory to standard forms of therapy and a life expectancy
of at least 2 months. Written informed consent was obtained
from all patients prior to entry. Eligibility criteria included
minimal haematological requirements of a total white cell
count of >4 x I09 per litre and a platelet count of > 100 x
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I09 per litre. In addition patients had normal liver func-
tion, urea and electrolytes, serum creatinine, uric acid, glu-
cose and coagulation screen. In the absence toxicity, a single
dose escalation was permitted in individual patients. The
starting dose was based on mouse and rat at toxicology.
Owing to the toxicity of the solvent DMSO an LD1O in mice
could not be obtained but was established to be greater than
420 mg m 2. The starting dose in the Phase I trial was
therefore approximately 1/10th of the LDIO in mice, i.e.
50mgm~2.
The pharmacokinetics of temozolomide were studied in
selected patients at each dose level and blood samples col-
lected into heparinised tubes just prior to temozolomide
administration and at 0.5, 1.0, 1.5, 2.0, 2.5, 3, 4, 5, 6, 8, 12
and 24 h post dosing.
Sample collection
All syringes and tubes for the collection of samples were
pre-cooled to 4°C and samples maintained at that tempera-
ture. Blood samples were transferred to lithium heparinised
tubes and immediately centrifuged at 2,000 r.p.m. for 10 min
at 4°C. Known volumes of plasma, whole blood or urine
were transferred to sterilin bijoux pots containing 1 N HC1
(0.1 ml ml ' fluid) and stored at - 18°C until analysis.
Plasma temozolomide
To 0.1 ml acidified plasma, was added 75 glI internal standard
(ethyl analogue of temozolomide) solution. Three ml ethyl
acetate was added, vortexed for 2 x 10 s, and centrifuged at
3,000 r.p.m. for 10 min. Two ml organic layer was transfer-
red to sample concentrator tubes and evaporated to dryness
at 45°C. A further 3 ml ethyl acetate was added to the
remaining aqueous phase which was then vortexed and cent-
rifuged. Three ml organic layer was removed and transferred
to the sample concentrator tubes containing the dried residue
of the first extraction. After evaporation to dryness, the
residue was reconstituted in 125 gil methanol and 125 glI 0.5%
acetic acid added. Samples were transferred to 0.4 ml mic-
rofuge vials and centrifuged in a Beckman microfuge for
5 min. The supernatant was taken for analysis by HPLC
Calibration
To 0.1 ml acidified plasma, whole blood or urine (0.1 ml 1 N
HCI/1.0 ml fluid) known amounts of temozolomide were
added in 0.1 N HCI between the range 0.2 and 6gig ml-'. A
volume of 0.1 N HCI was added to make a total of 75 gIl
using a solution of 1% DMSO in 0.1 N HCI.
HPLC analysis
The samples were analysed utilising a Waters WISP 710B,
510 pump, 480 UV detector and a 840 data and chromato-
graphy control station. The chromatographic conditions
were: Column - Lichrosorb RP-Select B (125 x 4 mm), UV -
325 nm, mobile phase - 10% methanol in 0.5% acetic acid,
flow rate - 1.8 ml min-', injection volume - 0.035 ml. Temo-
zolomide retention time 2.0 min internal standard 4.5 min
(Slack et al., 1985).
Results
The trial has been conducted in two parts: the first 51
patients were treated with the single dose schedule. Their
mean age was 52 years and their diagnoses were melanoma,
14; renal, four; breast, four; colorectal, four; stomach, three;
glioma, three; others 15. Doses of temozolomide up to 200 mg
m-2 were administered intravenously. Oral bioavailability at
this latter dose was studied in five patients who received
temozolomide both orally and intravenously on two separate
occasions at least 4 weeks apart. Data from each patient are
presented in Table I and that of one patient presented in
Figure 2. Having demonstrated good bioavailability at
200mgm-2 subsequent dose escalations up to 1,200 mgm2
were given orally. The pharmacokinetics of temozolomide is
linear with dose (Figure 3). Parameters obtained in nine
patients dosed intravenously and in 25 patients following oral
administration are summarised in Table II.
After intravenous administration, plasma temozolomide
concentrations declined biexponentially and could be describ-
ed by a two compartment model with a distribution half life
of 1.8 h. After oral dosing however, plasma concentrations in
most instances have been fitted to a one compartment model.
Temozolomide was rapidly absorbed, with maximum plasma
concentrations being attained 0.7 h post dosing. Over the
concentration range studied, temozolomide pharmacokinetics
were not dose dependent and the relationship between dose
and the area under the plasma concentration vs time curve
was linear (r = 0.858), see Figure 3. Clearance of temozolo-
mide was estimated to be 11.8 1 h-'. Plasma temozolomide
concentrations in some patients displayed a secondary
absorptive phase as late as 4 h post dosing which is likely to
reflect entero-hepatic recycling.
The data relating to the two patients receiving oral
temozolomide on three separate occasions indicates that
INTRA-subject variability in plasma concentrations is small.
Pharmacokinetics of temozolomide during the 5 day sche-
dule have only been studied in one individual when plasma
concentrations were determined on Day 1 and Day 5. There
was no accumulation of temozolomide - the area under the
plasma concentration vs time curve being 34.8 and 23.1 mg
Ih-' on Days 1 and 5 respectively.
The symptomatic toxicity from temozolomide on the single
dose schedule was mainly nausea and vomiting. This was
usually mild to moderate (WHO 1-3) at doses up to 700 mg
m-2 but at higher doses some patients experienced Grade 4
Table I Po vs i.v. AUCS
i.v. Oral
AUC0 AUC
Patient (mg h I-') (mg h 1-') Fb
05 32.16 41.00 1.27
07 33.12 32.32 0.98
15 35.96 41.67 1.16
17 23.55 31.94 1.36
19 25.30 16.93 0.67
Mean: 1.09
aArea under the curve calculated by the trapezoidal rule. bF
Bioavailabilitycalculated withoutconsideration ofthe small differences
in apparent elimination half life.
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Figure 2 Patient - 05; Dose - 200 (mg m-2); Half life - 2.16 (h);
Bioavailability - 1.27.PHASE I TRIAL OF TEMOZOLOMIDE 289
toxicity which in most cases could be controlled with stan-
dard antiemetics. Alopecia when it could be assessed was
Grade 0-1. A mild erythematous skin rash was seen in two
patients. Haematological toxicity was dose limiting on the
single dose schedule (see Tables III and IV) and, unlike
mitozolomide the haematological toxicity was more predict-
able, but was severe in cachectic patients. No clinical re-
sponses were seen with the single dose schedule.
In view of the schedule dependency of temozolomide anti-
Table II Summary of pharmacokinetic parameters
Parameter Mean value n CV (%)
Volume of distribution (1) 28.30 43 39
Elimination half life (h) 1.81 48 20
Distribution half life (h) 0.26 17 64
Clearance (I h-') 11.76 42 35
200 -
190 -
180 -
170 -
_ 160-
I -1nE 'I lbu
-
- 140-
s 130-
, 120-
E 110-
100-
(-) 90-
) 80-
< 70-
0. 60-
X 50-
I 40
30
20
10- ; -
0 0.2 0.4 0.6 0.8 1 1.2
Temozolomide dose (g m-2)
Figure 3
Table III Temozolomide Phase I: toxicity leukopenia
Dose level Evaluable WHO grade
(mg m-2) courses 0 1 2 3 4
50 4 3 1 - - -
100 9 8 1 -
150 4 4 - - - -
200 18 17 1 - - -
250 5 4 1 - - -
300 5 3 2 - - -
360 2 2 - - - -
430 1 1 - - - -
520 9 9 - - - -
700, 750 14 14 - - - -
900, 920, 1,000 25 11 2 5 4 3
1200 1 1 - - - -
(Single dose schedule) 97 evaluable courses.
Table IV Temozolomide Phase I: toxicity thrombocytopenia
Dose level Evaluable WHO grade
(mg m-2) courses 0 1 2 3 4
50 4 4 - - - -
100 9 8 - 1
150 4 4 - - - -
200 18 18 - - - -
250 5 5 - - - -
300 5 5 - - - -
360 2 2 - - - -
430 1 1 - - - -
520 9 9 - - - -
700, 750 14 14 - - - -
900, 920, 1,000 25 13 5 2 3 2
1,200 1 1 - - - -
(Single dose schedule) 97 evaluable courses.
tumour activity in mice (Stevens et al., 1987), doses of 750,
900, 1,000 and 1,200mgm-2 were administered as a 5 day
schedule in 42 patients on a 4 week cycle (Table V). Nausea
and vomiting on this schedule was usually limited to Day 1
and was readily controlled with antiemetics. In contrast to
mitozolomide the 5 day schedule of temozolomide was not
more myelosuppressive than the single dose schedule (Schor-
nagel et al., 1986). In order to avoid occasional Grade 4
haematological toxicity, it is recommended that the initial
course should be at a dose of 150 mgm2 po for 5 days
(total dose 750mgm2), on a 4 week cycle. If no major
myelosuppression is detected on day 22 of the 4 week cycle,
the subsequent courses can be given at a dose of 200 mg m-2
po for 5 days (total dose 1 g m-2) which was in general well
tolerated haematologically (Tables VI and VII). Over a 19
month period nausea and vomiting on the 5 day oral sche-
dule of 750 mgm2 (total dose), was WHO grade 0 in 11
(29%); one in seven (18%); two in nine (24%); three in ten
(26%); four in one (3%) in 38 evaluable courses. At 1,000 mg
m-2 (total dose), the nausea and vomiting was WHO grade 0
in 25 (49%); one in five (10%); two in 15 (29%); three in six
(12%); four in 0 (0%) in 51 evaluable courses. Non haemato-
logical toxicity was mild with alopecia WHO grade 1 in one
patient, skin rash grade 2 in one patient and renal toxicity
grade 1 in one patient. Constipation and headaches occurring
in several patients were attributed to concurrent ondansetron.
Table V Temozolomide Phase I: patient characteristics
(5 day schedule)
Total number of patients entered:
Number of courses administered:
At 750 mg m-2
At 900mgm 2
At 1,000 mgm 2
At 1,200 mg m-2
Females:
Males:
Median age: (range 20-83 years)
Performance status (WHO):
0
1
2
3
Unknown
Diagnosis:
Melanoma
Ovary
Lymphoma
Glioma
Other
42
103
35
20
45
1
17
25
49.5
12
15
11
1
3
23
3
3
4
9
Two courses were not evaluable for toxicity on Tables VI and VII for
the following reasons: (i) no laboratory results were taken after last
course; (ii) early death following last course.
Table VI Temozolomide Phase I: toxicity leukopenia
Dose level Evaluable WHO grade
(mg m-2) courses 0 1 2 3 4
750 35 35 - - -
900 20 20 - - -
1,000 45 36 6 2 - 1
1,200 1 - - - - 1
(5 day schedule) 101 evaluable courses.
Table VII Temozolomide Phase I: toxicity thrombocytopenia
Dose level Evaluable WHO grade
(mg m 2) courses 0 1 2 3 4
750 35 35 - - - -
900 20 20 - - - -
1,000 45 38 - 3 3 1
1,200 1 - - - - 1
(5 day schedule) 101 evaluable courses.290 E.S. NEWLANDS et al.
Clinical experience so far shows little cumulative toxicity
associated with temozolomide at this dose which is much
easier to handle than mitozolomide.
Evidence of clinical activity was seen in a number of
patients (Table VIII). The Phase I trial was targeted towards
melanoma since at physiological pH, temozolomide spontan-
eously activates to MTIC the putative active metabolite of
dacarbazine, an existing anti-melanoma agent (Figure 1). A
total of 14 patients with metastatic melanoma were entered
on the single dose schedule dose between 50 and 1,000mg
m-2 but no responses were seen. Twenty-three patients with
melanoma were entered on the 5 day schedule with doses
between 750 and 1,200 mg m-2. A complete response lasting
6 months was seen in one patient with recurrent cutaneous
metastases and a very good partial response lasting 7 months
was seen in a patient with pulmonary and hepatic disease
(the patient having a complete response on chest X-ray from
multiple pulmonary metastases). Two other patients with
melanoma responded for 4 and 5 months respectively pro-
ducing a response rate of four (17%) out of 23 patients. One
patient with drug resistant mycosis fungoides (previous
chemotherapy included vincristine, chlorambucil, predniso-
lone, bleomycin, etoposide, methotrexate, cyclophosphamide,
adriamycin and mitozantrone), had a dramatic response last-
ing 7 months and has currently achieved a second complete
remission after restarting temozolomide. In addition, activity
has been seen in recurrent high grade gliomas. Clinical
improvement was seen in two patients with glioma during the
dose escalation part of the study. Temozolomide is known to
cross the blood brain barrier in mice (P. Antoniw, E.S.
Newlands, unpublished observations) and therefore further
patients with glioma were entered in this trial. To March
1991 good partial responses on CT scan with dramatic clini-
cal improvements have been seen in two patients with recur-
rent high grade gliomas after prior surgery and radiotherapy
(Table XII).
Discussion
Temozolomide is an analogue of mitozolomide but, unlike
the latter drug, can be readily administered orally on a 5 day
schedule. The new drug usually elicits predictable and reversi-
ble myelosuppression. Doses up to 1 g m2 (given in equal
doses over 5 days) can be administered with acceptable
haematological toxicity and with little evidence of cumulative
toxicity. Clinical activity has been seen in malignant mela-
noma, mycosis fungoides and high grade gliomas. The
recommended dose for further studies is 750mgm-2 split
over 5 days and if no myelosuppression is detected on day 22
blood counts subsequent courses can be given at 1 g m-2 split
over 5 days given orally and repeated on a 4 week cycle.
Distribution studies performed in mice confirmed that temo-
zolomide like mitozolomide (Brindley et al., 1986 and unpub-
lished observations), has good tissue distribution including
penetration into tumour tissue and the central nervous
system. This extended Phase I study indicates that temozo-
lomide warrants further evaluation in Phase II studies in
melanoma, gliomas and lymphoma and other tumour types.
The toxicology and Phase I studies of temozolomide have been
performed under the auspices of the Cancer Research Campaign
Phase I/II Committee.
Table VIII Temozolomide responses
Dose level No. of
mgm-2 courses Response Duration Tumour type Offstudy
1 1,000 single dose 1
750 over 5 days 9 Complete 6 months Melanoma Yes
2 1,000 over 5 days 4 Complete 7 months Mycosis fungoides Yes
- skin
1,000 over 5 days 4 Complete 2 months No
- skin
- ongoing
3 750 over 5 days 9 Partial 7 months Melanoma Yes
- lungs, liver
4 1,000 over 5 days 5 Partial 4 months Melanoma Yes
- regional node
5 1,000 over 5 days 4 Partial 5 months Melanoma Yes
- axillary lump
6 1,000 over 5 days 7 Partial 7 months Glioma Yes
7 1,000 over 5 days 1 Partial 2 months Glioma No
750 over 5 days 2 - ongoing
References
BLACKLEDGE, G., ROBERTS, J.T., KAYE, S.B. & 4 others (1989).
Phase II study of mitozolomide in metastatic transitional cell
carcinoma of the bladder. Eur. J. Cancer Clin. Oncol., 25, 391.
BRINDLEY, C.J., ANTONIW, P. & NEWLANDS, E.S. (1986). Plasma
and tissue disposition of mitozolomide in mice. Br. J. Cancer, 53,
91.
BULL, V.L. & TISDALE, M.J. (1987). Antitumour imidazotetrazines
XVI. Macromolecular alkylation by 3-substituted imidazotetra-
zines. Biochem. Pharmacol., 36, 3215.
GIBSON, N.W., HARTLEY, J.A., MA17TES, W.B., KOHN, K.W. &
ERICKSON, L.D. (1985). The effects of pretreatment of human
tumour cells with MNNG on the DNA crosslinking and cytotox-
icity of two chloroethylating agents. Abstract: International Con-
ference on Mechanisms ofDNA Damage and Repair. Implications
for Carcinogenesis and Risk Assessment. Gaithersburg: Mary-
land. June 2-7.
GIBSON, N.W., HICKMAN, J.A. & ERICKSON, L.D. (1984). Effects of
the antitumour agent 8-carbamoyl-3-(2-chloroethyl)imidazo[5, 1-
d]l,2,3,5-tetrazin-4(3H)-one on the DNA of mouse L1210 cells.
Cancer Res., 44, 1767.
GIBSON, N.W., HICKMAN, J.A. & ERICKSON, L.D. (1985). DNA
crosslinking and cytotoxicity in normal and transferred human
cells treated in vitro with 8-carbamoyl-3-(2-chloroethyl)-imidazo
[5-1-d],1,2,3,5-tetrazin-4(3H)-one. Cancer Res., 44, 1772.
GUNDERSON, S., AAMDAL, S. & FODSTAD, 0. (1987). Mitozolomide
(NSC35451), a new active drug in the treatment of malignant
melanoma. Phase II trial in patients with advanced disease. Br. J.
Cancer, 55, 433.
HARDING, M., NORTHCOTT, D., SMYTH, J., STUART, N.S.A.,
GREEN, J.A. & NEWLANDS, E.S. (1988). Short communication in:
Phase II evaluation of mitozolomide in ovarian cancer. Br. J.
Cancer, 57, 113.PHASE I TRIAL OF TEMOZOLOMIDE 291
HARTLEY, J.A., GIBSON, N.W., KOHN, K.W. & MATTES, W.B. (1986).
DNA sequence selectivity of guanine-N7 alkylation by three
antitumour chloroethylating agents. Cancer Res., 46, 1943.
HERIAT, P., ROUGIER, P., OLIVEIRA, J. & 4 others (1988). Phase II
study of mitozolomide (M&B39565) in colorectal and breast
cancer. Invest. New Drugs, 6, 323.
NEIJT, J.P., VAN DER BURG, M.E., GUASTALLA, J.P., GEORGE, M.,
VERMORKEN, J.B. & ROTMENTSZ, N. (1987). Mitozolomide in
patients with advanced ovarian carcinoma: a Phase II study of
the EORTC Gynaecological Cancer Cooperative Group. Ab-
stract: Proc., ECCO-4. Fourth European Cancer Conference on
Clinical Oncology and Cancer Nursing; Federation of European
Cancer Studies, Madrid. p. 214. Nov 1-7.
NEWLANDS, E.S., BLACKLEDGE, G., SLACK, J.A. & 4 others (1985).
Phase I clinical trial of mitozolomide. Cancer Treatment Reports,
69, 7-8 July/Aug.
SCHORNAGEL, J.H., SIMONETTI, G. & MCVIE, J.G. (1986). Phase I
study of mitozolomide (NSC 54351) using a daily x 5 schedule.
Proc. Fifth NCI-EORTC Symposium on New Drugs in Cancer
Therapy. Abstract.
SLACK, J.A. & GODDARD, C. (1985). Antitumour imidazotetrazines
VII. Quantitative analysis of mitozolomide in biological fluids by
HPLC. J. Chromatogr., 337, 178.
STEVENS, M.F.G., HICKMAN, J.A., LANGDON, S.P. & 11 others
(1987). Antitumour activity and pharmacokinetics in mice of 8-
carbamoyl-3-methylimidazo [5,1-d] 1, 2, 3, 5-tetrazin-4 (3H) one
(CCRG) 81045; M&B 39831) a novel drug with potential as an
alternative to dacarbazine. Cancer Res., 47, 5846.
STEVENS, M.F.G., HICKMAN, J.A., STONE, R. & 4 others (1984).
Antitumour imidazotetrazines 1. Synthesis and chemistry of 8-
carbamoyl-3-(2-chloroethyl) imidazo [5, 1, d] -1, 2, 3, 5-tetrazin-
4(3H)- one, a novel broad spectrum antitumour agent. J. Med.
Chem., 27, 196.
TSANG, L.L.H., QUARTERMAN, C.P., GESCHER, A. & SLACK, J.A.
(1991). Comparison of the cytotoxicity in vitro of temozolomide
and dacarbazine, prodrugs of 3-methyl-(triazen-1-yl)imidazole-4-
carboxide. Cancer Chemother. Pharmacol., 27, 342.
VAN OOSTEROM, A.T., STOTER, G., BONO, A.V. & 6 others (1989).
Mitozolomide in advanced renal cancer: a phase II study in
previously untreated patients from the EORTC Genitourinary
Tract Cancer Cooperative Group. Eur. J. Cancer Clin. Oncol., 25,
1249.